List of bibliographic references
Number of relevant bibliographic references: 4.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 4 | Female |
| 4 | Hepacivirus (drug effects) |
| 4 | Humans |
| 4 | Male |
| 4 | Middle Aged |
| 4 | Treatment Outcome |
| 3 | Adult |
| 3 | Drug Therapy, Combination |
| 3 | Hepatitis C, Chronic (drug therapy) |
| 3 | Liver Cirrhosis (drug therapy) |
| 2 | Aged |
| 2 | Antiviral Agents (therapeutic use) |
| 2 | Hepacivirus (classification) |
| 2 | Hepacivirus (genetics) |
| 2 | Hepatitis C, Chronic (complications) |
| 2 | Liver Cirrhosis (virology) |
| 2 | Oligopeptides (therapeutic use) |
| 2 | Young Adult |
| 1 | Administration, Oral |
| 1 | Anemia (etiology) |
| 1 | Antiviral Agents (administration & dosage) |
| 1 | Benzimidazoles (therapeutic use) |
| 1 | Benzofurans (administration & dosage) |
| 1 | Biomechanical Phenomena (drug effects) |
| 1 | Biopsy, Needle |
| 1 | Blood Coagulation Disorders, Inherited (complications) |
| 1 | Blood Coagulation Disorders, Inherited (diagnosis) |
| 1 | Blood Coagulation Disorders, Inherited (drug therapy) |
| 1 | Dose-Response Relationship, Drug |
| 1 | Drug Administration Schedule |
| 1 | Fluorenes (therapeutic use) |
| 1 | Follow-Up Studies |
| 1 | Genotype |
| 1 | Global Health |
| 1 | Health Services Accessibility |
| 1 | Hepacivirus (physiology) |
| 1 | Hepatitis C (complications) |
| 1 | Hepatitis C (drug therapy) |
| 1 | Hepatitis C (physiopathology) |
| 1 | Hepatitis C (virology) |
| 1 | Hepatitis C, Chronic (diagnosis) |
| 1 | Hepatitis C, Chronic (mortality) |
| 1 | Hepatitis C, Chronic (virology) |
| 1 | Imidazoles (administration & dosage) |
| 1 | Immunohistochemistry |
| 1 | Intention to Treat Analysis |
| 1 | Interferon-alpha (administration & dosage) |
| 1 | Liver (drug effects) |
| 1 | Liver (pathology) |
| 1 | Liver (physiopathology) |
| 1 | Liver Cirrhosis (complications) |
| 1 | Liver Cirrhosis (mortality) |
| 1 | Liver Cirrhosis (physiopathology) |
| 1 | Liver Function Tests |
| 1 | Multivariate Analysis |
| 1 | Oligopeptides (administration & dosage) |
| 1 | Oligopeptides (adverse effects) |
| 1 | Oligopeptides (pharmacology) |
| 1 | Polyethylene Glycols (administration & dosage) |
| 1 | Quinoxalines (administration & dosage) |
| 1 | RNA, Viral |
| 1 | Recombinant Proteins (administration & dosage) |
| 1 | Reference Values |
| 1 | Ribavirin (administration & dosage) |
| 1 | Ribavirin (therapeutic use) |
| 1 | Risk Factors |
| 1 | Severity of Illness Index |
| 1 | Time Factors |
| 1 | Uridine Monophosphate (analogs & derivatives) |
| 1 | Uridine Monophosphate (therapeutic use) |
| 1 | Viral Load |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Massimo Colombo"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "Massimo Colombo" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Massimo Colombo
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
